Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

Livdelzi will launch at a list price of $12,606 for a 30-day treatment cycle, a little higher than the $11,500 per month set by Ipsen for Iqirvo, which is a dual PPAR alpha/delta agonist.

Iron-dependent ferroptosis, a non-apoptotic cell death mechanism, is gaining attention for its role in immune suppression.

After hours: March 21 at 7:45:35 PM EDT Loading Chart for TPST ...

Berkshire Hathaway Inc., through its subsidiaries, engages in the insurance, freight rail transportation, and utility businesses worldwide. The company provides property, casualty, life, accident ...

As noted above, stellate cell activation is the central event in hepatic fibrosis. Activation consists of 2 major phases: (1) initiation (also called apreinflammatory stage) and (2) perpetuation ...

Sino Biopharmaceutical Limited (“Sino Biopharm” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a ...